Not provided
Not provided
Not provided
Not provided
Practice on postoperative pain management changed
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The combination of different analgesic drugs and/or analgesia techniques is part of the standard management of postoperative analgesia. The analysis of the literature reveals a lack of comparison of the associations of non-opioid analgesic (NOA) with morphine for postoperative analgesia.
The objectives of this study are :
Since the description of the concept of balanced analgesia in the early 90's, the combination of different analgesic drugs and/or analgesia techniques is part of the standard management of postoperative analgesia. A recent survey conducted in France by Fletcher et al. showed that patients often received one or more NOA associated with an opioid. The benefit and risk of the use of opioids associated with NOA were recently reassessed as part of a formal recommendation of experts and detailed in a recent review. The analysis of the literature reveals a lack of comparison of the combinations of NOA with morphine for postoperative analgesia. For example, paracetamol and morphine in combination does not always allow a significant morphine-sparing effect compared with morphine alone and does not reduce the incidence of morphine side effects. A number of definitive answers has therefore yet to be found: Does NOA -morphine association allow an effective morphine-sparing effect? Is there an interest in prescribing several NOAs in association? If yes, what are the most interesting combinations in terms of morphine-sparing effect and safety?
Another question concerns the effects of NOA on postoperative hyperalgesia. This hyperalgesia, which results from surgery-related inflammation, is increased by consumption of morphine and not only contributes to the overall experience of postoperative pain but also to the chronicisation of postoperative pain. Since in clinical practice, hyperalgesia can be measured using specific tools (Von Frey filament type), our study will evaluate the anti-hyperalgesic effects of NOA on a subgroup of patients enrolled in the centers used to evaluate nociceptive thresholds.
The objectives of this study are :
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Control group C: Placebo | Placebo Comparator | All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours. |
|
| Group P: Paracetamol | Experimental | All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours. |
|
| Group N: Nefopam | Experimental | All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours. |
|
| Group K: Ketoprofen | Experimental | All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours. |
|
| Group PN: paracetamol and nefopam | Experimental | All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Paracetamol | Drug |
|
| Measure | Description | Time Frame |
|---|---|---|
| Morphine consumption (mg), accumulated over 24 hours, measured by patient controlled analgesia (PCA). | Day 1 |
| Measure | Description | Time Frame |
|---|---|---|
| Morphine consumption (mg) measured by patient controlled analgesia (PCA). | Day 2, day 3 | |
| Incidence of side effects associated with morphine: nausea, vomiting, sedation, urinary retention, pruritus. | Day 3 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| ERIC BELLISSANT | Rennes University Hospital | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Karine Nouette-Gaulain | Bordeaux | France | ||||
| Marcel Chauvin |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 30915987 | Derived | Beloeil H, Albaladejo P, Sion A, Durand M, Martinez V, Lasocki S, Futier E, Verzili D, Minville V, Fessenmeyer C, Belbachir A, Aubrun F, Renault A, Bellissant E; OCTOPUS group. Multicentre, prospective, double-blind, randomised controlled clinical trial comparing different non-opioid analgesic combinations with morphine for postoperative analgesia: the OCTOPUS study. Br J Anaesth. 2019 Jun;122(6):e98-e106. doi: 10.1016/j.bja.2018.10.058. Epub 2018 Dec 29. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Group PK: paracetamol and ketoprofen | Experimental | All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours. |
|
| Group NK: nefopam and ketoprofen | Experimental | All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours. |
|
| Group PNK: paracetamol, nefopam and ketoprofen | Experimental | All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours. |
|
| Nefopam | Drug |
|
| Ketoprofen | Drug |
|
| Morphine | Drug |
|
|
| Area of hyperalgesia measured using a von Frey filament expressed in cm2, 48 hours after surgery (sub-study in 3 centers). | Day 2 |
| Incidence of chronic pain assessed by a telephone questionnaire 3 months after surgery (sub-study in 3 centers). | Month 3 |
| Global satisfaction (measured after treatment) | Day 3 |
| Boulogne |
| France |
| Hawa Keita-Meyer | Colombes | France |
| Dominique Fletcher | Garches | France |
| Pierre Albaladejo | Grenoble | France |
| Frédéric Aubrun | Lyon | France |
| Xavier Capdevila | Montpellier | France |
| Hervé Bouaziz | Nancy | France |
| Karim Asehnoune | Nantes | France |
| Marc Raucoules | Nice | France |
| Jacques Ripart | Nîmes | France |
| Anissa Belbachir | Paris | France |
| Emmanuel Marret | Paris | France |
| Jean-Xavier Mazoit | Paris | France |
| Marc Beaussier | Paris | France |
| Sébastien Bloc | Quincy-sous-Sénart | France |
| Jean-Marc Malinovsky | Reims | France |
| Marc Gentili | Saint-Grégoire | France |
| Vincent Minville | Toulouse | France |
| ID | Term |
|---|---|
| D000082 | Acetaminophen |
| D009340 | Nefopam |
| D007660 | Ketoprofen |
| D009020 | Morphine |
| ID | Term |
|---|---|
| D000083 | Acetanilides |
| D000813 | Anilides |
| D000577 | Amides |
| D009930 | Organic Chemicals |
| D000814 | Aniline Compounds |
| D000588 | Amines |
| D010079 | Oxazocines |
| D001392 | Azocines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D010666 | Phenylpropionates |
| D000146 | Acids, Carbocyclic |
| D002264 | Carboxylic Acids |
| D009022 | Morphine Derivatives |
| D009019 | Morphinans |
| D053610 | Opiate Alkaloids |
| D000470 | Alkaloids |
| D006572 | Heterocyclic Compounds, Bridged-Ring |
| D006576 | Heterocyclic Compounds, 4 or More Rings |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D010616 | Phenanthrenes |
| D011084 | Polycyclic Aromatic Hydrocarbons |
| D011083 | Polycyclic Compounds |
Not provided
Not provided